Findings

What do systematic reviews say?

4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Lanadelumab vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.07 [0.77, 1.47]
2 studies · 158 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Avoralstat vs placebo

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Adverse events (during · children or adults with Types I or II HAE

Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.16]
1 study · 24 participants
Low

Berotralstat vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.63 [0.39, 1]
1 study · 37 participants
Low

Berotralstat vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Low

Zinc oxide mesh vs placebo mesh

Proportion of wounds healed · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

The review found no eligible studies for this question.

3 findings from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found
Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
RR 2.35 [0.49, 11.23]
1 study · 64 participants
Very low

Zinc oxide mesh vs placebo mesh

Cost‐effectiveness · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

The review found no eligible studies for this question.

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc oxide mesh vs placebo mesh

Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

The review found no eligible studies for this question.

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc oxide mesh vs placebo mesh

Adverse effects (surgical site infection or allergic reaction) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
GRADE not reported

Zinc oxide mesh vs placebo mesh

Time to complete healing · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease

1 finding from 1 review

Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal… 2022 · Cochrane Headline outcomes only
no estimate extracted
54 participants
Low

Hydrocortisone vs placebo

Severity of PTSD symptoms · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propranolol vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Severity of PTSD symptoms ‐ Clinician‐rated · adults (aged 18 and older) exposed to a traumatic event

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Gabapentin vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

PTSD rate at 3 months · adults (aged 18 and older) exposed to a traumatic event

It is very uncertain whether gabapentin changes PTSD rate at 3 months compared with placebo (very low certainty).

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 0.8 [0.18, 3.59]
1 study · 26 participants
Very low

Gabapentin vs placebo

Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gabapentin vs placebo

Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

Dropouts due to adverse events · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrocortisone vs placebo

PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event

The review found no eligible studies for this question.

1 finding from 1 review

Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found